We are redefining the standard of care.
By 2030, there will be more than 150 million people in the United States alone that have or are at risk of fatty liver disease, with the majority underdiagnosed.
With VelacurTM, there’s now a practical office-based solution to assess liver tissue stiffness and attenuation in patients with chronic liver disease.
VelacurTM quantifies ultrasound attenuation (component of liver fat measurement) and tissue stiffness (component of liver fibrosis measurement) in the liver. Our portable solution consists of a handheld ultrasound, which is placed between the patient’s ribs, and an activation pad. The patient lies on the activation pad, which creates steady state waves in the liver and a 3D tissue sample is measured.
The entire procedure can take 5 minutes to complete, producing real-time measurements to aid in the management of patients with liver disease.